At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 154 enrolled
Drug / intervention
AZD1722 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Exploratory Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Design Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AZD1722 in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria
In Brief
A Phase 2 clinical trial evaluating AZD1722 and Placebo for Chronic Kidney Disease and Type 2 Diabetes Mellitus. Completed, enrolled 154 participants across 1 site.
Detailed Summary
The purpose of this study is to determine if the study drug is safe, tolerable and active in reducing albuminuria in patients with Chronic Kidney Disease with Type 2 Diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Kidney Disease, Type 2 Diabetes Mellitus
CountriesUnited States
CollaboratorsAstraZeneca
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2013
First PostedMay 2013
Primary CompletionMar 2015
Study CompletionApr 2015
TodayJul 2026
First PostedMay 6, 2013
Enrollment StartMay 1, 2013
Primary CompletionMar 1, 2015
Study CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 13.2 years ago
Interventions
AZD1722drug
Placebodrug
Placebo for AZD1722